WTR Healthcare Happenings

In this episode of WTR Healthcare Happenings, Tommy Barletta, Co-Founder and Managing Partner of ALDIS Institutional Services, joins host Tim Gerdeman, Co-Founder of Water Tower Research, to discuss what next week’s midterm elections could mean for healthcare investors. ALDIS Institutional Services is an independent research provider that pairs policy expertise with Washington and Wall Street rela...

In this episode of WTR Healthcare Happenings, Anthony Tennyson, CEO of Solvonis Therapeutics (LSE: SVNS), joins WTR healthcare analyst Robert Sassoon and host Tim Gerdeman, Co-Founder of Water Tower Research, to discuss the latest developments in the company’s clinical-stage pipeline targeting addiction and other CNS disorders. The conversation explores new analysis supporting SVN-001 for alcohol...

In this episode of WTR Healthcare Happenings, Robert Sassoon, Managing Director and Healthcare Analyst at Water Tower Research, joins host Tim Gerdeman, Co-Founder of Water Tower Research, to discuss his newly published initiation of coverage on PharmAla Biotech Holdings (CSE: MDMA, OTCQB: MDXX). Robert Sassoon explains how the Toronto-based company built two businesses on a single chemical and re...

In this episode of WTR Healthcare Happenings, Robert Sassoon, Managing Director of Healthcare Equity Research at Water Tower Research, joins host Tim Gerdeman to discuss his newly published initiation of coverage on Circular Genomics, a privately held molecular diagnostics company developing blood-based tests using circular RNA (circRNA) biomarkers. Robert Sassoon explains the science behind circR...

In this episode of WTR Healthcare Happenings, Robert Sassoon, Managing Director and healthcare analyst at Water Tower Research, joins host Tim Gerdeman to discuss his newly published initiation of coverage on eXoZymes (Nasdaq: EXOZ) and its cell-free biomanufacturing platform. Robert Sassoon explains how the technology works, the significance of the reported 10-fold productivity improvement in NCT...

In this episode of WTR Healthcare Happenings, Kirk Huntsman, CEO of Vivos Therapeutics (NASDAQ: VVOS), joins WTR healthcare analyst Robert Sassoon and host Tim Gerdeman to break down the company's financial and operational restructuring. Kirk Huntsman details the work underway to strengthen the balance sheet, including debt reduction, equity requirements, and Nasdaq compliance. The conversati...

In this episode of WTR Healthcare Happenings, Natural MedTech CEO and Co-Founder Luke McFarlane joins WTR healthcare analyst Robert Sassoon and Shawn Severson to discuss the company's biosynthetic psilocybin manufacturing platform and its position within Australia's evolving psychedelic medicine landscape. The conversation covers the authorized prescriber pathway, including adoption tren...

In this episode, Cannara Biotech COO and Interim CFO Nick Sosiak joins WTR's Linda Bolton Weiser and Tim Gerdeman to discuss the company's expansion following the announcement of a long-term international supply agreement with Curaleaf carrying a potential aggregate value of up to C$21 million. The conversation covers Cannara's differentiated approach within the cannabis industry, t...

In this episode of WTR Healthcare Happenings, Oncolytics Biotech CEO Jared Kelly joins WTR's Tim Gerdeman and healthcare analyst Robert Sassoon to discuss the company's progress advancing pelareorep, its investigational oncolytic virus immunotherapy for difficult-to-treat gastrointestinal cancers. The conversation covers the significant unmet need in RAS-mutated colorectal, pancreatic, a...

In this episode of WTR Healthcare Happenings, Doug Drysdale, biopharma veteran and founder of Katagen, former CEO of Cybin (now Helus Pharma), joins WTR's Tim Gerdeman and analyst Robert Sassoon to explore whether psychedelic medicine has moved from speculative niche to mainstream therapeutic category. The discussion covers Eli Lilly's $2.8 billion upfront acquisition of Atai Beckley and...

Dr. Elazar Sonnenschein, Founder and CEO of Pulsenmore Ltd. (Nasdaq and Tel Aviv: PLSM), joins host Tim Gerdeman and WTR equity research analyst James Kisner on this episode of the WTR Healthcare Happenings Podcast. Pulsenmore has built the first FDA De Novo–authorized, prescription home-use prenatal ultrasound, allowing expectant mothers to capture images on a handheld device for remote physician...

In this episode of WTR Healthcare Happenings, host Tim Gerdeman is joined by healthcare equity research analyst Robert Sassoon to discuss the rebound in biotech and pharma M&A. Robert explains why 2026 is shaping up as the strongest M&A environment since 2019, with 35 disclosed-value deals totaling roughly $97 billion in just over six months.  The discussion covers rising deal sizes, the p...

In this episode, Christer Rosen, Founder and CEO of Jupiter Neurosciences (Nasdaq: JUNS), and President & COO Alison Silva join Water Tower Research’s Tim Gerdeman and Healthcare Analyst Robert Sassoon to discuss Jotrol, the company’s proprietary micellar formulation of resveratrol engineered to overcome long‑standing bioavailability and tolerability limitations. Jotrol has demonstrated a nine...

In this episode of Healthcare Happenings, Robert Sassoon, WTR healthcare equity analyst, joins host Tim Gerdeman to discuss his initiation of coverage on NurExone Biologic (TSXV: NRX / OTCQB: NRXBF), a preclinical biopharma company advancing a novel exosome platform targeting CNS regeneration. Sassoon walks through the science behind exosome therapeutics, NurExone's differentiated ExoTherapy...

In this episode of Healthcare Happenings, Nick Kadysh, Founding CEO and President of PharmAla Biotech (CSE: MDMA / OTCQB: MDXXF), joins host Tim Gerdeman and WTR healthcare analyst Robert Sassoon to discuss two recently announced transactions. The first is the formation of Restora Neuroscience, a special purpose vehicle created to advance APA01, a non-controlled neurology molecule, through a precl...

In this special episode of the WTR Healthcare Happenings podcast, the second in a two-part series, Professor David Nutt, Chief Science Officer of Solvonis Therapeutics (LSE: SVNS), talks to host Tim Gerdeman and WTR analyst Robert Sassoon about addiction and why he believes Solvonis' novel approach offers potentially better solutions than are currently available. The discussion also covers pe...

In this special episode of Healthcare Happenings , the first in a two‑part series, Anthony Tennyson, CEO of Solvonis Therapeutics (LSE: SVNS), joins host Tim Gerdeman and WTR analyst Robert Sassoon to discuss the company’s strategy in addiction and psychiatry — a field with significant unmet need and limited effective treatment options. Anthony walks through SVN‑001, a ketamine‑based therapy for s...

In this episode of Healthcare Happenings, John Lai, CEO of PetVivo Holdings (PETV), joins host Tim Gerdeman and WTR analyst Robert Sassoon to discuss the company's regenerative medicine platform for companion animals. The conversation covers PetVivo's product suite led by Spryng, its cartilage-mimicking protein particle matrix; the off-the-shelf Precise PRP product; and a BioPiezo collab...

 In this episode of the WTR Healthcare Happenings podcast, Stephen Rodgers, Head of Global Planning and Strategy at SBC Medical Group Holdings (NASDAQ: SBC), joins WTR’s Tim Gerdeman and Robert Sassoon. Rodgers discusses how SBC’s 26‑year build‑out into a 283‑location platform serving 2.1 million customers with a 72% repeat rate has created a scale, data, and trust advantage that competitors have...

ExoZymes (NASDAQ: EXOZ) CEO Michael Heltzen joins Tim Gerdeman and Robert Sassoon in this episode of the WTR Healthcare Happenings podcast to discuss the company’s AI-driven, cell-free biomanufacturing platform and how it aims to overcome longstanding scalability challenges in synthetic biology. The conversation covers the scientific differentiation of its “exozyme” enzyme engineering approach, th...

On the latest WTR Healthcare Happenings podcast, we were joined by David Sans, PhD, a healthcare investment banker, and our host, Tim Gerdeman, WTR’s Vice-Chair, Co-Founder, and Chief Marketing Officer . Over the past two years, Sans has focused on a corner of the market most investors overlook: publicly listed companies with low or negative shareholders’ equity and stock prices trading below $1....

On this episode, Vivos Therapeutics (NASDAQ: VVOS) CEO Kirk Huntsman joins WTR’s Tim Gerdeman and Robert Sassoon on Healthcare Happenings to discuss the company’s 2025 results and the momentum behind its shift from a dentist‑led model to a medically integrated strategy centered on sleep centers and physician referrals, anchored by the Sleep Center of Nevada acquisition. Huntsman highlights strong...

Water Tower Research's healthcare equity analyst Robert Sassoon breaks down President Trump's executive order on therapeutic psychedelics, examining the five key mechanisms it puts in place — from accelerated FDA review vouchers and right-to-try expansion to federal funding and ibogaine pathway clearance. Sassoon explains what the order gets right, where it falls short (namely on reimbur...

In this special preview episode of WTR Healthcare Happenings, Robert Sassoon spotlights two biotechs presenting on Day 1 of the WTR Insights Conference (April 14–15) . Nurexone Biologic (TSX-V: NRX | OTCQB: NRXBF) is pioneering an exosome-based therapy for spinal cord injury and other CNS conditions, with Phase 1/2A trials expected to initiate within 12 months. Anixa Biosciences (NASDAQ: ANIX) is...

In this episode of the WTR Healthcare Happenings podcast, Water Tower Research’s Shawn Severson and Robert Sassoon are joined by Dr. Paul Sargeant, President and CEO of Circular Genomics, a privately held molecular diagnostics company developing next‑generation blood tests based on circular RNA biomarkers. The conversation explores the science behind circular RNA, the company’s product pipeline, i...